Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
The VEGF receptor inhibitor AZD2171 diminished breast tumor size in cancer models
March 9th, 2006
The vascular endothelial growth factor (VEGF) receptor inhibitor AZD2171 diminishes breast tumor size in cancer models. According to research from the United States, "This pilot study combined physiologic imaging, microcomputed tomography, and histologic tumor evaluation with a xenograft model of breast cancer to identify surrogates likely to correlate with response to AZD2171, an inhibitor of the VEGF receptor tyrosine kinases." "MCF-7 cells transfected with vector (MCF-7(nec)) or VEGF (MCFVEGF) were implanted in the right and left mammary fat pads of 75 athymic mice. Treatment with AZD2171 (5 mg/kg/d) or vehicle control was initiated once tumors...
Source: Women's Health Weekly (2006-03-09)
|
